Why did ATS Medical choose to acquire the SurgiFrost cryoablation system from CryoCath Technologies?
ATS Medical is focused on delivering innovative solutions to cardiac surgeons that help advance the standard of care for their patients. The SurgiFrost cryoablation system and the associated proprietary technology represent innovation that addresses the clinical needs of patients with atrial fibrillation with the efficacy and ease of use important to the cardiac surgeon and their patients. In 2003, ATS Medical completed a comprehensive assessment of the surgical technologies available to treat patients with cardiac arrhythmias. This analysis indicated the superior results achieved with cryoablation versus other energy sources. In November 2004, ATS announced our distribution and agency partnership with CryoCath which enabled ATS to provide cardiac surgical cryoablation devices to the worldwide marketplace. Over the past two years, the surgical ablation business for patients with atrial fibrillation has grown rapidly and the clinical data demonstrating the superior efficacy rates for cr
